Last reviewed · How we verify

Salbutamol sulphate 6 mg

Boehringer Ingelheim · FDA-approved active Small molecule Quality 5/100

Salbutamol sulphate 6 mg is a Small molecule drug developed by Boehringer Ingelheim. It is currently FDA-approved.

At a glance

Generic nameSalbutamol sulphate 6 mg
SponsorBoehringer Ingelheim
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Salbutamol sulphate 6 mg

What is Salbutamol sulphate 6 mg?

Salbutamol sulphate 6 mg is a Small molecule drug developed by Boehringer Ingelheim.

Who makes Salbutamol sulphate 6 mg?

Salbutamol sulphate 6 mg is developed and marketed by Boehringer Ingelheim (see full Boehringer Ingelheim pipeline at /company/boehringer-ingelheim).

What development phase is Salbutamol sulphate 6 mg in?

Salbutamol sulphate 6 mg is FDA-approved (marketed).

Related